Introduction
Inflammation is an important aetiological factor of cardiovascular diseases such as atherosclerosis and restenosis. 1 Inflammation regulation is required at multiple levels to limit inflammation damage. Although the nuclear factor kappa B (NF-jB) plays a central role in the activation of gene transcription involved in inflammatory responses, 2, 3 several studies implicated sirtuin 1 (SIRT1) in the inhibition of inflammatory responses. 4, 5 The reduction of SIRT1 increases vascular cell senescence and enhances vascular inflammation. 6 Notably, SIRT1 blocks Ang IIinduced NF-jB binding on the promoter of monocyte chemoattractant protein-1 (MCP-1/CCL2) and inhibited its expression. 6 The targets for SIRT1 deacetylation are key components of the intracellular inflammatory response. For example, SIRT1 deacetylates eNOS, and increases NO bioavailability in endothelium with beneficial effects on vascular homeostasis. 7 Furthermore, SIRT1 inhibits NF-jB, leading to enhanced cell death in response to tumour necrosis factor alpha (TNF-a). 8 Overexpression of SIRT1 alleviates vascular remodelling induced by angiotensin II (AngII) infusion, and significantly inhibits vascular inflammation in mouse thoracic aorta and renal arteries. 9 However, the effect of SIRT1 on anti-inflammatory signalling has not been elucidated in VSMCs. Smooth muscle (SM) 22a is a 22 kDa actin-associated protein abundant in SMCs of vertebrates. 10 SM22a activity is necessary for maintaining the differentiated phenotype of VSMCs. 11, 12 Emerging evidence suggests an important role for SM22a in the pathogenesis of a variety of human diseases. SM22a loss in apolipoprotein E knockout mice leads to enlarged atherosclerotic lesions with prominent macrophage infiltration, a sign of enhanced inflammation. 13 Recently, the aortic transcriptome of SM22a -/-mice reveals that SM22a loss can actively contribute to the pathogenesis of atherosclerosis. In fact, Sm22a knockout results in an increased expression of pro-inflammatory genes which are controlled by NF-jB in the aortas. 14 We have demonstrated that SM22a interacts with and stabilizes IjBa to inhibit NF-jB p65 nuclear translocation and activation. 15 The expression of SM22a resembles that of SIRT1 in terms of the regulation of VSMC phenotypes, including high expression in contractile state, inhibiting proliferation and inflammation. However, the relationship between SM22a and SIRT1 in the control of vascular inflammation is not fully understood. Enhancer of zeste homolog 2 (EZH2), a methyltransferase, mediates histone 3 Lys-27 trimethylation (H3K27me3). 16 EZH2 activity is positively regulated by acetylation and phosphorylation. 17 However, whether EZH2 is involved in epigenetic regulation of VSMC marker genes remains unclear.
In this study, we demonstrate that, in response to TNF-a stimulation, casein kinase (CK)II-SIRT1-SM22a acts in a loop to reinforce the expression of SM22a, which limits the inflammatory response in VSMCs in vivo and in vitro. The anti-inflammatory effect of SIRT1 may be dependent on SM22a to some extent. Our findings provide new evidence that SM22a inhibits vascular inflammation and may be therapeutically exploited to prevent cardiovascular diseases.
Methods Animals
All animal procedures conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication, 8th Edition, 2011) and was approved by the Institutional Animal Care and Use Committee of Hebei Medical University. The Sm22a knockout mouse line (B6.129S6-Taglntm2(cre)Yec/J), which has a Cre-recombinase gene inserted into the endogenous SM22a locus, was purchased from the Jackson Laboratory. SMC-SIRT1 transgenic mice were kindly provided by Dr De-Pei Liu (PhD, Chinese Academy of Medical Sciences and Peking Union Medical College). The Sirt1-Tg mice were developed as previously described.
18 Sirt1-Tg mice were crossbred with Sm22a knockout mice to obtain Sm22a
-/-/Sirt1-Tg mice. The resulting breeding offsprings were analysed for the presence of the transgenic human Sirt1 protein and the Sm22a -/-genotype through tail tip DNA analysis, as described earlier.
14 SpragueDawley rats were obtained from the Experimental Animal Center of Hebei Medical University. Male mice of at least 9 weeks of age were used for experiments.
Carotid artery ligation models
Nine-to twelve-week-old male mice underwent a complete carotid artery ligation. Briefly, male Sm22a
-/-/Sirt1-Tg, and wild-type (WT) mice were anesthetized by inhalation of isoflurane-N 2 O (F 1 O 2 0.35, 0.015 L/ L isoflurane). The left common carotid artery was completely ligated just near its bifurcation using a 6-0 silk ligature.
Haematoxylin and eosin (H&E) staining and immunohistochemistry
Carotid arteries were harvested at 14 days after injury. The animals were euthanized by an intraperitoneal injection of ketamine (80 mg/kg)/xylazine (5 mg/kg). The left ventricle was cannulated and perfused with phosphate buffered saline (PBS) containing heparin, and then perfused and fixed with 4% paraformaldehyde in PBS under physiological pressure. The left carotid artery was then removed, further fixed for 16 h, and paraffin-embedded without further dissection. Serial sections (5-lm thick) were obtained at 500 lm proximal to the ligation site. The cross-sectional areas of the intima and media were measured in H&E stained sections in a blinded manner by a single observer using Image Pro Plus 6.0 software (Media Cybernetics). A mean value was determined from at least 4 sections for each animal. Neointima formation was determined as the ratio of the intimal area to the medial area (I/M). The immunohistochemical analyses were processed according to standard procedures. Immunostaining of sections were preincubated with 5% normal goat serum and then incubated with anti-monocyte chemotactic protein ( The sections were incubated with the horseradish peroxidase streptavidin biotinylated secondary antibody (Dako) followed by diaminobenzidine (DAB kit, Vector Laboratories) and counterstained with Gill's haematoxylin (Fisher Scientific). For the negative controls, the primary antibody was replaced with non-immune rabbit or mouse serum. Staining intensities were determined by measurement of the integrated optical density (IOD) with light microscopy using a computer-based Image-Pro Morphometric System by two independent observers in a double-blind manner. IOD of objects expressing the protein (brown coloured) was compared with the overall number of cells counted on the basis of IOD blue-related nuclei. The results are expressed as the mean value of three randomly chosen slides in each group.
Cell culture and treatment
Male Sprague-Dawley rats, 80-100 g, were anesthetized with sodium pentobarbital (50 mg/kg, Sigma); VSMCs were prepared from medial explants of thoracic aortic tissue, and cultured in low glucose Dulbecco's-modified Eagle's medium (DMEM) (Invitrogen, Carlsbad, CA, USA) with 10% foetal bovine serum (FBS), 100 U/mL penicillin, and 100 lg/mL streptomycin. FBS was obtained from PAA Laboratories (Canadian Origin, NO. A15-751). VSMCs were maintained at 37 C in a humidified atmosphere containing 5% CO2 and only passage 3 to 5 cells at 70-80% confluence were used in the experiments, unless stated otherwise. VSMCs were made quiescent by serumstarvation for 24 h and then treated with TNF-a (10 ng/mL, PeproTech). For inhibitor studies, cells were pretreated for 2 h with a CKII inhibitor CX-4945 (Sigma, St Louis, MO, USA), the p38 inhibitor SB203530 (Promega), the extracellular signal-regulated kinas (ERK) inhibitor PD98059 (Sigma), the c-Jun N-terminal kinases (JNK) inhibitor SP600125 (Sigma), or the Akt inhibitor LY294002 (Sigma), before the addition of TNF-a. Each in vitro experiment was performed three times, with three samples in different wells (n = 9) and results were analysed using hierarchical statistics.
Small interfering RNA (siRNA) transfection
Cultured VSMCs were grown to 50-60% confluence and then transfected with specific duplex siRNAs. SM22a siRNA (siSM22a), 5'-GCUAGU GGAGUGGAUUGUATT-3' and 5'-UACAAUCCACUCCACUAGCTT-3', CKII siRNA (siCKII) 5'-CAAACUAUAAUCGUACAUC-3' and 5'-GAUG UACGAUUAUAGUUUG-3, EZH2 siRNA (siEZH2) was obtained from Life Technologies (Catalog # 4390771). Scrambled siRNA (siCon) 5'-GCUAGA GUAGCGGUGAAUUCGTT-3' and 5'-CGAAUUCAC CGCUACUCUAG CTT-3' served as a negative control. The siRNAs were transiently CKII-SIRT1-SM22a and vascular inflammation transfected into VSMCs using RNAi-MAX reagent (Invitrogen). Six hours after transfection, VSMCs were stimulated with TNF-a.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total RNA was extracted using TRIzol reagent (Invitrogen) and cDNAs were synthesized by reverse transcriptase SuperScript II (Invitrogen). The qRT-PCR was performed using SYBRV R Green Real-time PCR Master Mix (Invitrogen) and 7300 Real Time PCR System (Applied Biosystems, Carlsbad, CA, USA). For RT-PCR analysis, the following specific primers were used: 
Western blot analysis
Cells were prepared with lysis buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, pH 8.0, 0.2 mM Na 3 VO 4 , 0.2 mM phenylmethylsulfonyl fluoride (PMSF), and 0.5% Nonidet P (NP)-40). Equal amounts of protein (60-100 lg) were separated by 10% SDS-PAGE and electro-transferred onto a polyvinylidenefluoride (PVDF) membrane. Membranes were blocked with 5% non-fat milk in tris-buffered saline-Tween (TBST) for 2 h at room temperature and incubated with specific primary antibodies against ICAM-1 (1:500, sc-8439, Santa Cruz), VCAM-1 (1:500, sc-8304, Santa Cruz), MCP-1(1:400, Santa Cruz), SM22a (1:1000, ab14106, Abcam), green fluorescent protein (GFP, 1:1000, sc-9996, Santa Cruz), CKII (1:500, no.2079-1, Epitomics), SIRT1 (1:1000, no.04-1557, Millipore), EZH2 (1:1000, no.5246, Cell Signalling), H3K9 (1:1000, 07-442, Millipore), H3K27 (1:1000, ab6002, Abcam), hemagglutinin (HA, 1:800, H3663, Enzo Life Sciences), H3 (1:1000, 06-99, Millipore), or b-actin (1:1000, sc-47778, Santa Cruz) at 4 C overnight. The membranes were then incubated with IRDye800 V R conjugated secondary antibody (1:20 000, Rockland Biochemicals) for 1 h at room temperature, following scanning with the Odyssey Infrared Imaging System. The protein bands of interest were quantified using Quantity One software (Bio-Rad).
Immunoprecipitation assay
Cells were lysed in a buffer composed of 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 10 mM sodium phosphate, 10 mM NaF, 1 mM sodium orthovanadate, 2 mM PMSF, 10 lg/mL aprotinin, 10 lg/mL leupeptin, and 10 lg/mL pepstatin. After centrifugation, 100 lg of the clarified cell lysate was incubated with 30 lL protein G/A-agarose (Santa Cruz, CA) and 5 lg of anti-phosphor-Ser (sc-81514, Santa Cruz) or anti-acetyl Lysine (Ac-ly, ab80178, abcam) antibodies. After 24 h incubation, the immune complexes were centrifuged, and washed four times with ice-cold lysis buffer. The immunoprecipitated protein was further analysed by western blot as described above.
SIRT1 activity assay
SIRT1 activity was determined with a SIRT1 fluorometric kit (Biomol International) according to the manufacturer's instructions. This assay uses a small lysine-acetylated peptide, corresponding to K382 of human p53, as a substrate. The lysine residue is deacetylated by SIRT1 and this process is dependent on the addition of exogenous nicotinamide adenine dinucleotide (NAD þ ). The fluorescence values obtained in the absence of NAD þ did not differ from the blank. This assay was performed as previously described. 19 Values were determined by reading fluorescence on a fluorometric plate reader (Spectramax Gemini XPS; Molecular Devices) with an excitation wavelength of 360 nm and an emission wavelength of 460 nm. Calculation of net fluorescence included the subtraction of a blank consisting of buffer containing no NAD þ and expressed as a percentage of control. The SIRT1-dependent activity was calculated after subtracting fluorescence values obtained in the absence of NAD þ . In all cases, we confirmed the linearity of the reaction over time.
Luciferase reporter assay
Briefly, VSMCs were seeded in a 24-well plate and grown for 12 h. Cells were transfected with SM22a promoter reporter plasmids and pRL (Renilla reniformis)-TK plasmids using Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Twenty four hours after transfection, cells were treated with TNF-a for 24 h. Cells were then harvested and luciferase activities were measured using a dual luciferase assay kit (Promega, Madison, WI, USA). Specific promoter activity was expressed as the relative activity ratio of firefly luciferase to Renilla luciferase.
Chromatin immunoprecipitation (ChIP) assay 
Data analysis
Data analysis was performed by using SPSS version 16.0. Data are presented as the means ± SEM. Data from in vivo experiments were analysed with oneway analysis of variance (ANOVA), and pairwise comparison among groups was done with SNK-q test. Data from in vitro experiments were analysed with nested ANOVA that takes into account both the number of wells and the number of experiments. For all statistical comparisons, P < 0.05 was considered significant.
Results

Disruption of SM22a decreases SIRT1 anti-inflammation effect
Several studies implicated that SIRT1 suppresses inflammatory responses. [4] [5] [6] SIRT1 can function as an anti-inflammatory molecule with beneficial effects on vascular homeostasis. 7 We recently demonstrated that SM22a inhibited vascular inflammation. 15 To investigate the relationship between SIRT1 and SM22a in vascular inflammation, Sm22a -/-mice, which underwent carotid artery ligation. We evaluated the expression of inflammatory molecules, including MCP-1, VCAM-1, ICAM-1, and MMP-2/-9, using immunohistochemical staining. We showed that deletion of SM22a increased neointimal formation and inflammatory gene expression compared with wild-type (WT) mice. Conversely, these parameters were decreased by over-expression of SIRT1 in Sirt1-Tg mice ( Figure 1A) . However, the levels of inflammatory molecules were greater in the carotid arteries of Sirt1-Tg/Sm22a -/-mice compared with that of Sirt1-Tg mice and accompanied with aggravated neointimal Figure 1A) . To determine the transcriptional activity of these inflammatory molecules, we examined their mRNA levels in the injured arteries of Sirt1-Tg, Sirt1-Tg/Sm22a
, and WT mice. Consistently, the expression of these inflammatory genes increased in the injured-carotid arteries. Expression was, in turn, Sm22a
-/-> Sirt1-Tg mice ( Figure 1B) . Western blot analysis provided similar results ( Figure 1C) . The inflammatory response of the arteries of Sirt1-Tg/Sm22a -/-mice was obviously less than that of Sm22a -/-mice. These findings suggest that SIRT1 overexpression inhibits injury-induced vascular inflammation, which may be at least partly dependent on SM22a. We speculated that SM22a may contribute to SIRT1 anti-inflammatory activity associated with vascular diseases.
SM22a provides a molecular platform for CKII-mediated SIRT1 phosphorylation
SIRT1 activity is stimulated by phosphorylation. To explore how SM22a contribute to SIRT1 anti-inflammatory activity, we determined the effect of SM22a on SIRT1 phosphorylation in VSMCs. SM22a knockdown resulted in a decreased SIRT1 phosphorylation with unchanged total SIRT1 protein levels upon TNF-a stimulation ( Figure 2A) . Conversely, SM22a overexpression enhanced SIRT1 phosphorylation ( Figure 2B ). Furthermore, SIRT1 activity was measured by a specific fluorometric assay. SIRT1 activity positively correlated with SM22a expression in TNF-astimulated VSMCs ( Figure 2C ), implying that SM22a may facilitate SIRT1 phosphorylation and activation. Using a panel of kinase inhibitors, we observed that TNF-a-induced SIRT1 phosphorylation was blocked by the CKII inhibitor CX-4945 ( Figure 2D ). CKII knockdown had a similar effect ( Figure 2E ). We next determined how SM22a facilitates the phosphorylation of SIRT1 by CKII. SM22a knockdown suppressed the interaction between CKII and SIRT1 ( Figure 2F ), implying that SM22a may act as a scaffold protein to bring together CKII and SIRT1. We next performed coimmunoprecipitation using anti-SM22a, anti-CKII, and anti-SIRT1 antibodies and showed that SM22a was present in the CKII-SIRT1 complex ( Figure 2G ). Taken together, these results suggest that SM22a recruits CKII to SIRT1 and, subsequently, facilitates SIRT1 phosphorylation. SM22a is required for SIRT1 activation in VSMCs in response to TNF-a stimulation. 
TNF-a down-regulates SM22a expression through increasing histone H3K27 trimethylation at its promoter
To understand the upstream regulatory mechanism by which SM22a expression is decreased under inflammatory conditions, we examined the expression pattern of SM22a at the mRNA and protein levels following TNF-a stimulation. SM22a mRNA and protein levels were reduced after TNF-a stimulation ( Figure 3A, B) . The treatment of VSMCs with TNF-a resulted in a decreased in Sm22a promoter activity ( Figure 3C ). SM22a is epigenetically suppressed in some inflammatory diseases such as cancers. 20, 21 As histone H3K9 and H3K27 trimethylation are linked to the transcriptional silencing of SMC marker genes, 22, 23 we quantified histone methylation in Sm22a promoter region using ChIP followed by quantitative PCR (ChIP-qPCR) assay. The H3K27me3, but not that of lysine 9 was enriched in Sm22a promoter region upon TNF-a stimulation ( Figure 3D, E) . To further confirm the epigenetic link between H3K27me3 and Sm22a transcriptional silencing, the binding activity of SRF, a key transcriptional regulator for SMC marker genes, was detected using ChIP assay. Following TNF-a stimulation, the recruitment of SRF to the Sm22a CArG box chromatin decreased under the same conditions, associated with an increase in H3K27me3 and transcriptional silencing ( Figure 3E ). These data indicate that TNF-a-induced H3K27me3 is involved in Sm22a epigenetic silencing.
EZH2 mediates H3K27me3 of Sm22a promoter
EZH2 is the major enzyme for H3K27 methylation. 24 We found that EZH2 overexpression increased TNF-a-induced global H3K27me3 levels ( Figure 4A ). Conversely, EZH2 knockdown resulted in a decrease in H3K27me3 levels ( Figure 4B ). ChIP-qPCR assay showed a significant increase in H3K27me3 and decrease in SRF recruitment at the Sm22a promoter region in EZH2-overexpressing VSMCs ( Figure 4C) . Moreover, luciferase reporter gene assay showed a decrease in Sm22a promoter activity under the same conditions ( Figure 4D ). These findings suggest that EZH2 mediates H3K27me3, contributing to Sm22a epigenetic repression under inflammatory conditions.
SIRT1 up-regulates Sm22a transcription via EZH2 deacetylation
A recent study demonstrated that EZH2 activity is regulated by acetylation, which enhances its capacity in suppressing target genes. 17 SIRT1
interacts with and deacetylates EZH2. 17 To investigate the mechanism underlying the regulation of EZH2 activity, we assessed EZH2 acetylation in response to TNF-a stimulation. TNF-a induced EZH2 acetylation in VSMCs ( Figure 5A ), which was abolished by a selective SIRT1 agonist, SRT1720 ( Figure 5B) . We next performed ChIP-qPCR assay to detect histone H3K27me3 of the Sm22a promoter. SRT1720 significantly decreased TNF-a-induced histone H3K27me3 of Sm22a promoter, accompanied by an increase of SRF binding to the Sm22a promoter ( Figure 5C ). The reporter gene assay also showed an increase in the promoter activity under the same conditions ( Figure 5D ). In addition, increased EZH2 acetylation was validated in the injured carotid artery of WT mice when compared with that of the sham mice ( Figure 5E ) and was abolished in the carotid arteries of Sirt1-Tg mice ( Figure 5F ). Taken together, these results indicate that SIRT1 may play a critical role in the maintenance of the homeostasis of SM22a expression. 
SIRT1 phosphorylation promotes its interaction with and deacetylation of EZH2
Recent studies indicated that SIRT1 phosphorylation increases its activity and substrate-binding affinity. 25 As mentioned above, CKII-mediated SIRT1 phosphorylation increased SIRT1 activity in VSMCs. Our next question was whether the CKII-SIRT1 axis is responsible for the regulation of EZH2 activity. CKII knockdown impaired the interaction of SIRT1 with EZH2 ( Figure 6A) . Similar results were observed in VSMCs treated with the CKII inhibitor CX-4945, suggesting that CKII is upstream of SIRT1, inactivating EZH2 ( Figure 6B ). Likewise, SM22a knockdown almost completely abolished the binding of SIRT1 to EZH2, coincident with the reduction of SIRT1 phosphorylation ( Figure 6C ). Taken together, these results suggest that SM22a recruits CKII to SIRT1 to facilitate SIRT1 phosphorylation and the subsequent deacetylation of EZH2, forming a loop regulating SM22a expression in response to TNF-a stimulation.
Discussion
In this study, we showed that SM22a deletion resulted in increased neointimal formation and inflammatory gene expression. Conversely, these measurements were decreased by over-expression of SIRT1 in Sirt1-Tg mice. Since vascular inflammation was slightly increased in Sirt1-Tg/ Sm22a -/-mice compared with that in Sirt1-Tg mice, we speculated that the ability of SIRT1 to inhibit injury-induced vascular inflammation may be at least partly dependent on SM22a. In the in vitro study, on one hand, we showed that TNF-a induced the epigenetic silencing of SM22a transcription via EZH2-mediated H3K27 methylation at SM22a promoter region, contributing to inflammatory response. On the other hand, TNFa simultaneously induced SIRT1 phosphorylation via CKII and, thereby, protected against inflammation. Phosphorylated SIRT1 interacted with and deacetylated EZH2 and, subsequently, promoted SM22a transcription by inhibiting EZH2 activity. In turn, increased SM22a facilitated the phosphorylation and activation of SIRT1 via recruitment of CKII to SIRT1, which amplified the anti-inflammatory effect of SIRT1. CKII-SIRT1-SM22a forms a loop that limits vascular inflammatory responses ( Figure 6D) . The basic molecular function of SM22a is to bind actin and to facilitate actin filament assembly and cytoskeletal rearrangements. A previous study demonstrated that SIRT1 can reduce neointima formation after injury by reducing cell proliferation and migration.
18 SIRT1 overexpression significantly inhibits ROS generation, vascular inflammation, and collagen synthesis in arterial walls. 10 CKII-mediated phosphorylation increases SIRT1 substrate binding affinity, deacetylase activity, and cellular response to DNA damage. 27 In this study, the interaction of SIRT1 with EZH2 was reduced following CKII knockdown, suggesting that CKII-mediated SIRT1 phosphorylation is required for its binding to EZH2. The acetylation of EZH2, which is reduced by SIRT1, affects its stability and capacity in repressing target genes. 17 The inhibition of SIRT1 increases EZH2 protein levels, and enhances its repressive action on the target gene expression, 17 suggesting that SIRT1 negatively regulates EZH2 activity. It is known that EZH2 also mediates histone H3K27me3 of the promoters of cytokine genes, 28 implying that EZH2 may be antiinflammation. In this study, we determined that EZH2 is a new substrate of SIRT1 that deacetylates and deactivates EZH2, thereby limiting vascular inflammation in TNF-a-induced VSMCs. Hence the anti-or proinflammatory action of EZH2 is dictated by the genes (cytokines or SM22a) being regulated.
We recently reported that CKII-mediated SM22a phosphorylation in VSMCs resulted in its dissociation from IjBa and RelA/p65 nuclear translocation upon TNF-a stimulation. 15 Here, we found that CKII phosphorylated SIRT1 in a SM22a-dependent manner under the same conditions, suggesting that a cross-talk between CKII and SM22a triggers opposite effects on vascular inflammatory responses. CKII interaction with SM22a not only promotes SIRT1 phosphorylation that exerts an antiinflammatory effect, but also facilitates IjBa phosphorylation and degradation that activates inflammatory signalling pathways. 15 Evidence indicates that the cellular microenvironment can play an essential role in the regulation of protein functions. 29, 30 CKII regulates some biochemical processes in a compartment-dependent fashion. CKII interaction with SM22a causes the turnover between SM22a degradation and expression triggered by TNF-a stimulation, determining the ultimate output of inflammatory signalling. 15 The balance among different compartment-specific components of CKII signals seems to be determinant for the vascular inflammation outcomes. However, the molecular mechanisms by which both SM22a and SIRT1 are distinctively selected by CKII require further investigations. Taken together, TNF-a not only induced an inflammatory response, but also simultaneously induced phosphorylation of SIRT1 via CKII, eliciting an anti-inflammatory protection. We identified a new molecular mechanism in which the CKII-SIRT1-SM22a loop negatively regulates vascular inflammation by reversing the inhibitory effect of EZH2-mediated H3K27 trimethylation and epigenetic silencing on Sm22a expression. SM22a plays a fine-tuned role in the amplitude control of vascular inflammation, and contributes to the anti-inflammatory effect of SIRT1. Based on the functional synergy between SIRT1 and SM22a in vascular inflammation, the upregulation of SIRT1 activity and SM22a expression may be a new therapeutic strategy for cardiovascular diseases. 
